Refractory Metastatic Colorectal Cancer

Oncology·MeSH: Colorectal Neoplasms

Prevalence

135.0 / 100K

Incidence

36.0 / 100K/yr

3 drugs in development·2 companies·2 clinical trials

Drug Pipeline by Phase

Phase 1(1)
DrugCompany
RP3Replimune Group, Inc. (REPL)

Compare drugs

Dabrafenib plus Trametinib vs RP3Dabrafenib plus Trametinib vs Dapagliflozin along with standard medical therapy

Frequently asked questions

How many drugs are in development for Refractory Metastatic Colorectal Cancer?

BioSniper tracks 3 drugs in development for Refractory Metastatic Colorectal Cancer across 2 companies.

How many clinical trials target Refractory Metastatic Colorectal Cancer?

There are 2 clinical trials targeting Refractory Metastatic Colorectal Cancer tracked by BioSniper.

What is the prevalence of Refractory Metastatic Colorectal Cancer?

The estimated prevalence of Refractory Metastatic Colorectal Cancer is approximately 135.0 per 100,000 population.

Deep-dive into Refractory Metastatic Colorectal Cancer

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Refractory Metastatic Colorectal Cancer — Drugs in Development & Clinical Trials | BioSniper